HappyMe brings skin care line to mass retailers
LOS ANGELES — HappyMe announced that its skin care line now is available at mass retailers.
HappyMe, which touts a line of acne and anti-aging treatments, was first distributed at select Duane Reade stores. The products are free of parabens, sulfates and synthetic dyes.
HappyMe’s selection of skin care products includes:
Overnight pimple eliminator;
The natural acne wash;
Natural acne healing moisturizer SPF 15;
Skin support dietary supplement;
The natural acne correction system, which includes the natural acne wash, natural acne healing moisturizer and akin support dietary supplement;
Pore and fine line perfector and primer;
Hand repair SPF 30; and
Neck and chest repair SPF 30.
“HappyMe delivers the same results as high-end spa products for a fraction of the price,” HappyMe Skincare spokesman Jeff Schroeder said. “By taking the most effective aspects of skincare and combining them into a single product line, HappyMe is producing results beyond any other mainstream skin care system.”
Report: Ranbaxy may sell generic Lipitor rights if unable to get FDA approval
NEW YORK — While Indian generic drug maker Ranbaxy Labs is expected by many to launch a generic version of a cholesterol drug made by Pfizer later this year, it may have to sell its rights to it if it can’t win Food and Drug Administration approval in time, according to published reports.
Citing Credit Suisse analysts, Bloomberg reported that the FDA may delay approval of Ranbaxy’s version of Lipitor (atorvastatin), which would prevent it from marketing the drug starting Nov. 30, as it has planned to do.
Still, according to Bloomberg, the company — mostly owned by Japan’s Daiichi Sankyo — is in discussions with the FDA.
Lipitor is the world’s top-selling drug, with more than $7 billion in sales in the United States, according to IMS Health data.
Sandoz sues Novo Nordisk over diabetes drug
NEW YORK — Generic drug maker Sandoz is suing Danish drug maker Novo Nordisk over a generic version of a drug used to treat diabetes, according to published reports.
Bloomberg reported that Sandoz, the generics arm of Swiss drug maker Novartis, was suing Novo Nordisk in a Detroit federal court, hoping the court would find that the Sandoz generic version of Novo Nordisk’s Prandin (repaglinide) did not infringe on the latter company’s patent covering the drug.
Sandoz is hoping to bring the drug to market before the drug loses patent protection, according to Bloomberg. The patent is scheduled to expire in June 2018, according to Food and Drug Administration records.